Nanotech's rising star in drug delivery; Halozyme books beaucoup revenue;

> The executive director of the Birla Institute of Scientific Research provides a broad overview on the status and future of nanotechnology in medicine. Item

>Halozyme booked nearly $23 million in revenue for its fiscal 2011 third quarter. The company also touts a number of upcoming milestones, including the reintroduction of Hylenex recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and ambulatory surgery centers. Release

>Arrowhead Research Corporation has published a white paper detailing its proprietary dynamic polyconjugate (DPC) technology to deliver siRNA. Release

>Alkermes' Vivitrol, an extended-release injectable drug to treat alcohol or drug dependence, has generated positive results in a new long-term 18-month study. Details

> DSM will supply Svelte a bioerodible drug carrier for a drug-eluting stent system. Story

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.